Amgen Cash Per Share vs Pb Ratio Analysis
AMGN Stock | USD 273.41 2.34 0.85% |
Amgen financial indicator trend analysis is way more than just evaluating Amgen Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amgen Inc is a good investment. Please check the relationship between Amgen Cash Per Share and its Pb Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Cash Per Share vs Pb Ratio
Cash Per Share vs Pb Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amgen Inc Cash Per Share account and Pb Ratio. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Amgen's Cash Per Share and Pb Ratio is -0.17. Overlapping area represents the amount of variation of Cash Per Share that can explain the historical movement of Pb Ratio in the same time period over historical financial statements of Amgen Inc, assuming nothing else is changed. The correlation between historical values of Amgen's Cash Per Share and Pb Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Per Share of Amgen Inc are associated (or correlated) with its Pb Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pb Ratio has no effect on the direction of Cash Per Share i.e., Amgen's Cash Per Share and Pb Ratio go up and down completely randomly.
Correlation Coefficient | -0.17 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Cash Per Share
Pb Ratio
Most indicators from Amgen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amgen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. At this time, Amgen's Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Tax Provision is likely to grow to about 1.4 B, while Enterprise Value Over EBITDA is likely to drop 13.42.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.2B | 1.4B | 2.9B | 3.0B | Depreciation And Amortization | 3.4B | 3.3B | 4.1B | 4.3B |
Amgen fundamental ratios Correlations
Click cells to compare fundamentals
Amgen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Amgen fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 59.7B | 62.9B | 61.2B | 65.1B | 97.2B | 102.0B | |
Short Long Term Debt Total | 29.9B | 33.0B | 33.3B | 38.9B | 64.6B | 67.8B | |
Other Current Liab | 8.5B | 9.2B | 9.9B | 11.2B | 13.7B | 14.4B | |
Total Current Liabilities | 12.8B | 11.7B | 12.2B | 15.7B | 18.4B | 19.3B | |
Total Stockholder Equity | 9.7B | 9.4B | 6.7B | 3.7B | 6.2B | 12.3B | |
Property Plant And Equipment Net | 4.9B | 4.9B | 5.2B | 5.4B | 6.6B | 3.6B | |
Net Debt | 23.9B | 26.7B | 25.3B | 31.3B | 53.7B | 56.4B | |
Retained Earnings | (21.3B) | (21.4B) | (24.6B) | (28.6B) | (26.5B) | (25.2B) | |
Cash | 6.0B | 6.3B | 8.0B | 7.6B | 10.9B | 11.5B | |
Non Current Assets Total | 41.3B | 41.8B | 41.8B | 42.9B | 66.8B | 70.2B | |
Non Currrent Assets Other | 2.2B | 5.6B | 6.5B | 5.9B | 9.0B | 9.4B | |
Cash And Short Term Investments | 8.9B | 10.6B | 8.0B | 9.3B | 10.9B | 10.5B | |
Net Receivables | 4.1B | 4.5B | 4.9B | 5.6B | 7.9B | 8.3B | |
Common Stock Shares Outstanding | 609M | 590M | 573M | 541M | 538M | 759.2M | |
Liabilities And Stockholders Equity | 59.7B | 62.9B | 61.2B | 65.1B | 97.2B | 102.0B | |
Non Current Liabilities Total | 37.2B | 41.9B | 42.3B | 45.8B | 72.5B | 76.2B | |
Other Current Assets | 1.9B | 2.1B | 2.4B | 2.4B | 1.9B | 2.7B | |
Other Stockholder Equity | (528M) | (985M) | 18.2B | 21.7B | 25.0B | 26.2B | |
Total Liab | 50.0B | 53.5B | 54.5B | 61.5B | 90.9B | 95.5B | |
Property Plant And Equipment Gross | 4.9B | 4.9B | 14.0B | 14.7B | 15.7B | 16.5B | |
Total Current Assets | 18.4B | 21.1B | 19.4B | 22.2B | 30.3B | 15.2B | |
Accumulated Other Comprehensive Income | (528M) | (985M) | (796M) | (231M) | (289M) | (274.6M) | |
Short Term Debt | 3.0B | 244M | 232M | 1.7B | 1.4B | 1.0B | |
Inventory | 3.6B | 3.9B | 4.1B | 4.9B | 9.5B | 10.0B | |
Accounts Payable | 1.4B | 1.4B | 1.4B | 1.6B | 1.6B | 1.7B | |
Common Stock Total Equity | 31.5B | 31.8B | 32.1B | 32.5B | 37.4B | 27.1B | |
Short Term Investments | 2.9B | 4.4B | 48M | 1.7B | 10.9B | 12.2B | |
Capital Stock | 31.5B | 31.8B | 32.1B | 32.5B | 33.1B | 27.5B | |
Common Stock | 31.5B | 31.8B | 32.1B | 32.5B | 33.1B | 27.5B | |
Other Assets | 955M | 1.3B | 6.5B | 2.2B | 2.5B | 1.4B | |
Long Term Debt | 27.0B | 32.9B | 33.2B | 37.4B | 63.2B | 66.3B | |
Property Plant Equipment | 4.9B | 4.9B | 5.2B | 5.4B | 6.2B | 5.3B | |
Good Will | 14.7B | 14.7B | 14.9B | 15.5B | 18.6B | 14.4B | |
Intangible Assets | 19.4B | 16.6B | 15.2B | 16.1B | 32.6B | 34.3B | |
Other Liab | 9.9B | 9.0B | 9.1B | 7.9B | 9.1B | 5.1B | |
Net Tangible Assets | (24.4B) | (21.9B) | (23.4B) | (27.9B) | (25.2B) | (23.9B) | |
Retained Earnings Total Equity | (21.3B) | (21.4B) | (24.6B) | (28.6B) | (25.8B) | (24.5B) | |
Long Term Debt Total | 27.0B | 32.9B | 33.2B | 37.4B | 43.0B | 29.9B | |
Non Current Liabilities Other | 9.6B | 9.0B | 2.5B | 2.7B | 2.3B | 2.2B |
Pair Trading with Amgen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.Moving together with Amgen Stock
Moving against Amgen Stock
0.85 | BMY | Bristol Myers Squibb | PairCorr |
0.82 | ESPR | Esperion Therapeutics | PairCorr |
0.68 | DYAI | Dyadic International | PairCorr |
0.6 | GILD | Gilead Sciences | PairCorr |
0.41 | DNA | Ginkgo Bioworks Holdings | PairCorr |
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.621 | Dividend Share 8.88 | Earnings Share 7.83 | Revenue Per Share 60.641 | Quarterly Revenue Growth 0.232 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.